In August 2020, we announced that an India based large global pharma has signed a term sheet with a Biotech client of Aagami. Now a definitive ag...
Published : 10 Mar 2021
Read MoreA Japanese BioPharma has chosen Aagami to find marketing / sales / distribution partner for their Lidocaine 10% Topical Patch, which is due for U...
Published : 09 Mar 2021
Read MoreAagami has completed 40+ one-on-one strategic meetings at Biotech Showcase which started during JPM week in January. As the meetings are online this t...
Published : 02 Feb 2021
Read MorePlease note that effective November 01, 2020, our office address has reverted to:Aagami Inc.2020 Calamos Court, Suite 200Naperville, Illinois 60563USA...
Published : 03 Nov 2020
Read MoreAagami is appointed by a Clinical stage French Pharma developing a smoking cessation drug extracted from natural tobacco leaf , for support...
Published : 23 Sep 2020
Read MoreAagami has been appointed by a Portugal headquartered Pharmaceutical Company dedicated to helping Pharmaceutical Customers bring new and off-patent dr...
Published : 18 Sep 2020
Read MoreAagami has succeeded in establishing a partnership for its Australian client which has a proven technology for producing high value(multi-billion doll...
Published : 28 Aug 2020
Read MoreWe have a new client, new assignment. A Texas based Pharma has appointed Aagami for divesting 2 oncology assets.The client, after acquiring a nov...
Published : 13 Aug 2020
Read MoreA Silicon Valley based company has appointed Aagami to support their investment needs. The client is developing and commercializing a ma...
Published : 24 Jul 2020
Read MoreAn Oakland, California based medical technology start-up developing the portable single-sided MRI, has appointed Aagami for supporting their need for ...
Published : 23 Jun 2020
Read More